HeartSciences Inc Warrant
HSCSW
3 hedge funds and large institutions have $53.8K invested in HeartSciences Inc Warrant in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
93% more capital invested
Capital invested by funds: $27.9K → $53.8K (+$26K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.14% less ownership
Funds ownership: 26.68% → 26.54% (-0.14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$55 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$281 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $31.8K | – | – | – |
|
|
2
Citadel Advisors
Miami,
Florida
| $22K | -$281 | -2,972 | -2% |
|
|
3
UBS Group
Zurich,
Switzerland
| $71 | +$55 | +586 | +117% |
|
HSCSW Hedge Fund Activity: Q1 2026 in Review
3 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in HeartSciences Inc Warrant (HSCSW) for Q1 2026, worth a combined $53.8K — up 93% from $27.9K a quarter earlier.
Fund positioning in HSCSW was balanced in Q1 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, adding an estimated $55. The largest seller was Citadel Advisors, cutting an estimated $281.
- 3 institutional investors held HeartSciences Inc Warrant (HSCSW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $53.8K of HeartSciences Inc Warrant stock for Q1 2026, up 93% quarter-over-quarter.
- 0 funds opened new HeartSciences Inc Warrant positions in Q1 2026 and 0 closed out.
- The largest HeartSciences Inc Warrant buyer in Q1 2026 was UBS Group, an estimated $55 added.
- The largest HeartSciences Inc Warrant seller in Q1 2026 was Citadel Advisors, an estimated $281 sold.
Based on aggregated 13F filings for Q1 2026.